I received a call from the physician doing the study, she ask that I post her contact information as she is actively seeking patients. Her email address is fshawwaf@florida-allergery.com Florida Ctr-Allergy & Asthma (280439)
9035 Sunset Drive
Miami, FL 33173
Florina Shawwaf, Screening/Recruitment Contact
305 931 7583
305.273.2988
RESEARCH STUDY SUMMARY
A clinical trial seeking patients for a research study for the treatment of Chronic Idiopathic Urticaria (CIU)
RESEARCH STUDY TITLE
A Phase IV, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Omalizumab Through 48 Weeks in Patients With Chronic Idiopathic Urticaria
PURPOSE
This randomized, double-blind, placebo-controlled study will evaluate efficacy and safety of subcutaneous omalizumab as an add-on therapy through 48 weeks. After completing an initial 24-week open-label treatment period with omalizumab 300 mg every 4 weeks, participants responding to omalizumab will be randomized at a 3:2 ratio (omalizumab:placebo) to either continue omalizumab or be transitioned to placebo for a further 24 weeks.
www.centerwatch.com/clinical-trials/listings/external-studydetails.aspx?StudyID=NCT02392624&CatID=811
Thanks,
Rebekah